The Indian market for biosimilar versions of AbbVie Inc.'s blockbuster biologic Humira (adalimumab) appears to have witnessed significant activity – there are an estimated seven brands already jostling for share. The segment has also seen an expanding patient pool and improved access amid interesting pricing dynamics.
First off the block was Zydus Cadila’s biosimilar adalimumab (marketed as Exemptia); launched in December 2014, Exemptia claimed to be a "fingerprint match" with the originator product in terms of safety, purity and potency. It was followed by Torrent Pharmaceuticals Ltd.’s version of adalimumab (marketed as Adfrar) launched in 2016